To summarize the open-label extension of VESPER-1, berobenatide 2.4 mg weekly demonstrated 16% weight loss at 32 weeks, a favorable benefit-risk profile for monthly dosing, and safety and tolerability consistent with the class with no discontinuations related to gastrointestinal adverse events, and the gastrointestinal tolerability was excellent, said John B
Our photometric findings further support this link, revealing temporally structured dopamine fluctuations surrounding running bouts (e.g
Because generics operate on tighter profit margins, manufacturers may have little ability to absorb increased costs
A pilot study of botulinum toxin injection for the treatment of delayed gastric emptying following esophagectomy
Glucocorticoids, stress, and fertility
This article explains the trial-based dosing approach, safety considerations, and how to access legitimate information